Showing results (1111-1120 of 1,142) with videos related to

Sort By:
Pageof 115
Science (New York, N.Y.)|January 23, 2025
Mechanically robust and stretchable organic solar cells plasticized by small-molecule acceptorsZhenye Wang, Di Zhang, Lvpeng Yang, et al.
BMJ Open|November 11, 2022
Relative vaccine effectiveness against Delta and Omicron COVID-19 after homologous inactivated vaccine boosting: a retrospective cohort studyLin Tang, Yanyang Zhang, Fuzhen Wang, et al.
Cell Discovery|December 19, 2023
Comprehensive genomic profiling of breast cancers characterizes germline-somatic mutation interactions mediating therapeutic vulnerabilitiesChao Chen, Cai-Jin Lin, Yu-Chen Pei, et al.
Translational Neurodegeneration|July 2, 2016
The recommendations of Chinese Parkinson's disease and movement disorder society consensus on therapeutic management of Parkinson's diseaseShengdi Chen, Piu Chan, Shenggang Sun, et al.
Science Advances|March 12, 2019
The endogenous retrovirus-derived long noncoding RNA TROJAN promotes triple-negative breast cancer progression via ZMYND8 degradationXi Jin, Xiao-En Xu, Yi-Zhou Jiang, et al.
BMC Complementary and Alternative Medicine|May 11, 2018
Antrodia cinnamomea extract inhibits the proliferation of tamoxifen-resistant breast cancer cells through apoptosis and skp2/microRNAs pathwayYu-Shih Lin, Yin-Yin Lin, Yao-Hsu Yang, et al.
Heliyon|July 24, 2023
The anti-SARS-CoV-2 effect and mechanism of Chiehyuan herbal oral protection solutionChing-Yuan Wu, Yao-Hsu Yang, Yu-Shih Lin, et al.
JAMA Oncology|August 14, 2020
Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical TrialKe-Da Yu, Fu-Gui Ye, Min He, et al.
BMJ (Clinical Research Ed.)|October 23, 2024
Intensive chemotherapy versus standard chemotherapy among patients with high risk, operable, triple negative breast cancer based on integrated mRNA-lncRNA signature (BCTOP-T-A01): randomised, multicentre, phase 3 trialMin He, Yi-Zhou Jiang, Yue Gong, et al.
Signal Transduction and Targeted Therapy|June 18, 2026
Spatially interpretable artificial intelligence framework to tailored neoadjuvant dual HER2 blockade in HER2-positive breast cancerXiang-Rong Wu, Hong Lv, Shen Zhao, et al.
Pageof 115